Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained before any assessment was performed.~* Male or female Chinese participants ≥ 50 years of age at the time of screening.~* Active CNV lesions secondary to AMD that affect the central subfield (including retinal angiomatous proliferation lesions with a CNV component) in the study eye at screening and confirmed by the Central Reading Center (CRC).~* Total area of CNV (including both classic and occult components) must comprise \> 50% of the total lesion area in the study eye at screening and confirmed by the CRC.~* Intra and/or subretinal fluid affecting the central subfield of the study eye at screening and confirmed by the CRC.~* BCVA between 78 and 23 letters, inclusive, in the study eye at screening and baseline using ETDRS testing.~Exclusion Criteria:~* Any active intraocular or periocular infection or active intraocular inflammation (e.g., infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis, uveitis) in study eye at baseline.~* Central subfield of the study eye affected by fibrosis or geographic atrophy assessed by color fundus photography at screening and confirmed by the CRC.~* Total area of fibrosis ≥ 50% of the total lesion in the study eye at screening and confirmed by the CRC.~* Subretinal blood affecting the foveal center point and/or ≥ 50% of the lesion of the study eye at screening and confirmed by the CRC.~* Previous treatment with any approved or investigational drugs for nAMD in the study eye (other than vitamin supplements).~* Retinal pigment epithelium rip/tear in the study eye at screening.~* Current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within 4 weeks prior to baseline.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brolucizumab 6 mg (Type: EXPERIMENTAL): 3 monthly intravitreal injections of brolucizumab 6 mg in the loading treatment period (q4w regimen) up to Week 8 followed by injections every 12 weeks (q12w regimen) or 8 weeks (q8w) up to Week 40 or Week 44, depending on disease activity status.
- Aflibercept 2 mg (Type: ACTIVE_COMPARATOR): 3 monthly intravitreal injections of aflibercept 2 mg in the loading treatment period (q4w regimen) up to Week 8 followed by injections every 8 weeks (q8w) up to Week 40.

Based on this trial design, predict the completion outcome and termination type (if applicable).